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Abstract
Intrathecal immunoglobulin G (IgG) synthesis, cerebrospinal fluid (CSF) oligoclonal IgG bands and lesional IgG
deposition are seminal features of multiple sclerosis (MS) disease pathology. Both the specific targets and
pathogenic effects of MS antibodies remain poorly characterized. We produced IgG1 monoclonal recombinant
antibodies (rAbs) from clonally-expanded plasmablasts recovered from MS patient CSF. Among these were a subset
of myelin-specific MS rAbs. We examined their immunoreactivity to mouse organotypic cerebellar slices by live
binding and evaluated tissue injury in the presence and absence of human complement. Demyelination, glial and
neuronal viability, and complement pathway activation were assayed by immunofluorescence microscopy and
compared to the effects of an aquaporin-4 water channel (AQP4)-specific rAb derived from a neuromyelitis optica
(NMO) patient. MS myelin-specific rAbs bound to discrete surface domains on oligodendrocyte processes and
myelinating axons. Myelin-specific MS rAbs initiated complement-dependent cytotoxicity to oligodendrocytes and
induced rapid demyelination. Demyelination was accompanied by increased microglia activation; however, the
morphology and survival of astrocytes, oligodendrocyte progenitors and neurons remained unaffected. In contrast,
NMO AQP4-specific rAb initiated complement-dependent astrocyte damage, followed by sequential loss of
oligodendrocytes, demyelination, microglia activation and neuronal death. Myelin-specific MS antibodies cause
oligodendrocyte loss and demyelination in organotypic cerebellar slices, which are distinct from AQP4-targeted
pathology, and display seminal features of active MS lesions. Myelin-specific antibodies may play an active role in
MS lesion formation through complement-dependent mechanisms.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system
(CNS) of unknown cause. Despite extensive patho-
logical characterization of heterogeneous MS lesions,
no consensus on the cellular and molecular mecha-
nisms driving diverse lesion pathology has emerged
[15, 24, 30]. The presence of persistent cerebrospinal
fluid (CSF) oligoclonal immunoglobulin G (IgG) bands
produced by intrathecal IgG synthesis in MS patients is
one of the most striking biochemical hallmarks of disease
[21]. Deposition of IgG and activated complement prod-
ucts are present in the most frequently seen Type II MS
lesions [15], suggesting a possible role of intrathecal IgG
in CNS tissue injury.
We have constructed recombinant monoclonal IgG1
antibodies (rAbs) from expanded CSF plasmablast clones
isolated from MS patients [22] and demonstrated their
differential patterns of binding to antigens expressed by
astrocytes and neurons or to myelin-enriched antigens
[3, 13]. In cDNA-transfected HEK cells or by protein im-
munoblotting of human brain lysate, myelin-specific rAbs
failed to recognize myelin-enriched proteins, including
myelin basic protein (MBP), proteolipid protein (PLP) and
myelin oligodendrocyte glycoprotein (MOG) [22], and
their specific targets remain elusive. Nevertheless, both
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myelin and neuron/astrocyte-targeted MS rAbs cause
myelin loss when applied to mouse spinal cord explant
cultures in the presence of human complement [3], indi-
cating that, similar to autoantibodies against aquaporin-4
(AQP4-IgG) in neuromyelitis optica (NMO) [2, 4, 28],
intrathecal IgGs in MS may contribute to lesion
pathogenesis.
In this study, we further investigated the primary effect
of myelin-specific MS rAbs on intact CNS tissue using
organotypic mouse cerebellar slice cultures. Our results
reveal that MS myelin-specific rAbs recognized surface
antigens on oligodendrocyte processes and the outer
layer of myelin ensheathing axons. In the presence of
human complement, these rAbs initiated classical com-
plement pathway activation leading to oligodendrocyte
death and rapid demyelination. The extent and timing of
glial and neuronal injury was distinct from damage
driven by AQP4-IgG and reproduced some hallmark fea-
tures of MS lesions, further distinguishing MS from
NMO and supporting an active role for intrathecal MS
IgG in CNS lesion formation.
Materials and methods
Animals
The care and euthanasia of animals were in accordance
with University of Colorado IUCAC policy for animal
use, which is in agreement with the NIH Guide for the
Care and Use of Laboratory Animals.
Recombinant antibodies
Myelin-specific MS monoclonal recombinant antibodies
(rAbs) used in this study were constructed from expanded
CSF plasma blast clones derived from a relapsing-
progressive MS patient 6 months after disease onset
(MS04-2, for rAb MS04-2#30 [22] or from an isolated
optic neuritis patient following their first clinical event
who subsequently progressed to clinically-definite MS
(ON07-7, for rAb MS07-7#49). NMO monoclonal recom-
binant anti-AQP4 antibody #53 (NMO#53) was cloned
from seropositive NMO patient CSF plasma blast [2], and
the isotype-control human antibody (Iso) was generated
from a chronic meningitis patient CSF plasma blast clone
[3]. All rAbs were expressed as full-length bivalent human
IgG1 antibodies containing a C-terminal Flag epitope
using a dual vector transient transfection system and puri-
fied with protein A-sepharose (Sigma-Aldrich, St. Louis,
MO) as previously described [2, 22]. All rAbs were used at
20 μg/ml in the slice cultures.
Cerebellar slice culture
Sagittal cerebellar slices (300 μm) were prepared from
PLP-eGFP mice [18] at P10 and cultured on MilliCell
0.4 μm membrane inserts (Millipore, Billerica, MA) for
10–14 days in slice media (25% Hank’s balanced salt
solution (HBSS), 25% heat-inactivated horse serum, 50%
minimum essential media (MEM), 125 mM HEPES,
28 mM D-Glucose, 2 mM L-Glutamine, 10U/ml penicillin/
streptomycin, all from Life Technologies, Carlsbad, CA) at
37 °C [29]. Prior to treatment, slices were switched to a
serum-free media (Neurobasal medium supplemented with
B27, 2 mM L-glutamine, 10U/ml penicillin/streptomycin
and 28 mM D-glucose).
Treatment of cerebellar slices
rAbs were applied at 20 μg/ml with or without 10% normal
or C5-depleted human serum (Complement Technology,
Tyler, TX). Media containing treatment reagents were ap-
plied both on top (50 μl) and below (250 μl) the membrane
insert. For live binding assays, unfixed slices were incu-
bated with 20 μg/ml rAbs for 4 h at 37 °C. Propidium iod-
ide (PI) (Sigma) was used at 5 μg/ml in the culture
medium to label dead cells in organotypic slice cultures.
Normal and C5-depleted human serum (Complement
Technology, Tyler, TX) were used at 10% (vol/vol) as the
source of human complement (HC).
Tissue preparation
For immunostaining, adult C57bl/6 mice were perfused
with 4% paraformaldehyde in phosphate-buffered saline
(PBS), and the brain was subsequently removed, post-
fixed overnight in 4% paraformaldehyde, and cryopro-
tected overnight in 20% sucrose at 4 °C. Mouse brain
was embedded in optimal cutting temperature (OCT)
freezing media, and 6–10 μm cryostat sections collected
on Superfrost Plus microscope slides (Fisher Scientific,
Pittsburgh, PA). Tissue sections were stored at −80 °C
until immunostaining.
Immunostaining
After treatment, cerebellar slices were rinsed twice with
PBS and fixed in 4% paraformaldehyde in PBS for
20 min at 4 °C. For immunohistochemistry, slices were
rinsed in PBS and permeabilized in 1.5 or 10% (myelin
proteins) Triton X-100 in PBS for 20 min. Slices were
rinsed, blocked with 5% normal donkey serum (NDS) in
PBS with 0.3% Triton X-100 for 1 h, and incubated with
primary antibodies overnight at room temperature.
Following 3 washes in PBS, Alexa Fluor-labeled sec-
ondary antibodies (Jackson ImmunoResearch, West
Grove, PA) were applied (1:800) overnight at room
temperature, washed 3 times in PBS and mounted in
Fluoromount G (Southern Biotech, Birmingham, AL).
The following primary antibodies were used: rabbit
anti-GFAP (Sigma), rabbit anti-Calbindin (Millipore),
mouse anti-MAG (Millipore), rabbit anti-MOG (Abcam,
Cambridge, United Kingdom), mouse anti-MBP (Covance,
Princeton, NJ), chicken anti- Neurofilament-H (Neuro-
mics, Minneapolis, MN), goat anti-Iba1 (Abcam), mouse
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anti-C3d (a gift from Dr. Joshua Thurman, University of
Colorado), rabbit anti-MAC complex (anti C5b-9,
Abcam), guinea pig anti- NG2 and rabbit anti-Olig2 (are
gifts from Dr. Charles Stiles, Harvard University).
Prior to immunostaining, PFA-fixed mouse cerebellum
tissue sections were thawed for 10 min, re-hydrated in
PBS for 10 min, and blocked in PBS containing 3% bo-
vine serum albumin (BSA), 2% normal goat serum
(NGS), and 0.3% Triton-X100 for 1 h. MS rAbs were ap-
plied at a final concentration of 20 μg/mL to mouse tis-
sues for 16 h at 4 °C in PBS containing 3% BSA and 2%
NGS. Tissue sections were then washed 3 times for
3 min with PBS. Alexa fluorescent secondary antibody
(1:1000) against human IgG (Molecular probes, Life
Science Technologies) was applied for 1 h at room
temperature in PBS containing 3% BSA and 2% NGS.
Tissue was then washed 5 times for 3 min in PBS
and mounted using Vectashield (Vector Laboratories,
Burlingame, CA, USA) containing DAPI.
Microscopy
Fluorescence images were acquired by Zeiss fluores-
cence microscope with Axiovision software (Zeiss, Jena,
Germany). Confocal images were acquired by Leica SP5
laser scanning microscope (Leica Microsystems GmbH,
Wetzlar, Germany). Super-resolution structured illumin-
ation microscopy was performed using Nikon’s N-SIM
(Nikon, Tokyo, Japan).
Quantification and statistical analysis
PLP-eGFP positive cell bodies in the cerebellar slices
were imaged using a Zeiss fluorescence microscope with
20X objective. Images were quantified with ImageJ
(National Institutes of Health open source). To quantify
the extent of myelination, we calculated the percentage
of total neurofilament-H staining that was co-labeled
with MBP using a Matlab algorithm (MathWorks,
Natick, MA). For each slice, 2–3 images were taken,
quantified, and averaged. Slices from 3–4 independent
experiments were analyzed. Statistical analyses were
performed by unpaired Student’s t test for single com-
parisons or by two-way ANOVA for grouped compari-
sons using GraphPad Prism software. Data are expressed
as means ± SD of independent experiments (n ≥ 3). Sig-
nificance is reported for p < 0.05.
Results
Myelin-specific MS rAb binds to oligodendrocyte
processes and myelinated axons
We examined the live binding pattern of the myelin-
specific MS rAb, MS04-2 #30 (MS#30) [3] in mouse orga-
notypic cerebellar slice cultures. MS#30 rAb co-localized
with myelin-associated glycoprotein-positive (MAG+) or
myelin oligodendrocyte glycoprotein-positive (MOG+)
axons (co-stained with neurofilament-H [NF-H], data not
shown) (Fig. 1a–h; stars), as well as enhanced green fluor-
escent protein-positive (eGFP+) oligodendrocyte processes
(Fig. 1a–h; arrows), although some oligodendrocyte pro-
cesses did not bind this antibody (Fig. 1e–g; arrow heads).
MS#30 reactivity was primarily located in discrete surface
domains external to MAG on myelinated axons or along
oligodendroglial processes projecting to axons with little
to no surface staining of oligodendrocyte cell bodies
(Fig. 1i; arrows and arrow heads; Online Resource,
Additional file 1: Video S1). The binding pattern suggests
that MS#30 recognizes an antigen produced and trans-
ported by oligodendrocytes to the myelin sheath (Fig. 1j).
MS#30 causes loss of mature oligodendrocytes in the
presence of human complement
We next examined the effects of MS#30 on ex vivo
cerebellar slices. Treatment with MS#30 plus human
complement (HC) resulted in altered oligodendrocyte
morphology and viability. As early as 8 h, oligodendro-
cyte processes were disorganized and fragmented
(Fig. 2a). By 48 h, there was complete loss of oligo-
dendrocyte processes, and the few remaining cell bodies
were hypertrophic and devoid of extended processes
(Fig. 2d). PLP-eGFP+ oligodendrocyte cell bodies dimin-
ished with continued exposure to MS#30 +HC (Fig. 2a–d).
At 8 h, we observed a 33.6 ± 7.2% loss compared to isotype
control rAb (Iso) plus HC (p < 0.001), and by 48 h, eGFP+
oligodendrocyte cell bodies were reduced by 73.1 ± 4.4%
(p < 0.0001). By comparison, there was a minor, but statisti-
cally significant loss (about 10%) of oligodendrocyte cells
following treatment with Iso +HC from 24 h (Fig. 2e, f),
which is consistent with our previous finding that HC
causes some modest oligodendrocyte loss in cerebellar
slices after 24 h treatment [14]. No changes in oligo-
dendrocyte morphology or viability were noted following
treatment with MS#30 in the absence of HC with preserva-
tion of 95.8 ± 2.7 and 101.9 ± 16.5% of eGFP+ oligodendro-
cyte cell bodies respectively at 24 h and 48 h when
compared to Iso treatment (Fig. 2g–j and data not shown).
Although MS#30 +HC caused significant damage to the
mature oligodendrocyte population as evidenced by loss of
eGFP+ cell bodies and processes, the oligodendrocyte pro-
genitor population was unaffected. Neither treatment with
MS#30 or MS#30 +HC induced changes to the morph-
ology or cell numbers of NG2+/Olig2+ (neural/glial anti-
gen 2; oligodendrocyte transcription factor 2) progenitors
at 24 h and 48 h (Fig. 2k–s).
MS#30-mediated demyelination is distinct from AQP4-
targeted demyelination
MS and NMO are both CNS inflammatory diseases
characterized by myelin loss. We next compared the pat-
tern and extent of MS#30 CNS demyelination with that
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caused by treatment with a pathogenic AQP4-specific
rAb, NMO#53, which was derived from an expanded
plasma blast clone isolated from NMO IgG-positive CSF
[2]. Concomitant with oligodendrocyte cell loss, MS#30 +
HC treatment showed a rapid and progressive loss of
myelin basic protein (MBP) along axons that was first
observed at 8 h after exposure (Fig. 3a–d, m; com-
pare 3a and i). Slices treated with NMO#53 + HC also
exhibited progressive myelin loss beginning at 12 h
(Fig. 3e–h, n; compare 3f and j) with MBP staining
displaying a distinct patchy and ‘debris-like’ pattern. De-
myelination under this scenario follows complement-
dependent destruction of astrocytes and is accompanied
by significant oligodendrocyte cell loss [13]. There were
no measurable effects on MBP staining of slices treated
with Iso +HC or HC alone (Fig. 3i–l, o and data not
shown). To assess the extent of cerebellar demyelination,
we quantified the percent of MBP-covered NF-H+ axons.
Treatment with MS#30 +HC caused a significant 34.5 ±
10.6% loss of MBP at 8 h (p < 0.05) that increased to a
91.0 ± 8.6% loss at 48 h (p < 0.0001). Demyelination oc-
curred later in slices treated with NMO#53 +HC, with a
36.6 ± 5.1% loss beginning at 12 h (p < 0.01), and reaching
62.3 ± 9.0% (p < 0.001) MBP loss at 48 h (Fig. 3p). In the
absence of HC, neither MS#30 nor NMO#53 induced de-
myelination (Fig. 3q–s).
Fig. 1 MS rAb #30 (MS#30) binds to oligodendrocyte processes and myelinated axons. Live cerebellar slices prepared from PLP-eGFP mouse pups
were incubated with 20 μg/ml MS#30 rAb (red), then fixed and immunostained with anti-human IgG secondary and the indicated myelin markers.
Confocal images of slices co-stained for the myelin proteins MAG (a–d; blue) and MOG (e–h; blue). MS#30 staining was co-localized with PLP-eGFP+
oligodendrocyte processes (arrows) and MAG+ or MOG+ myelinated axons (stars). Not all oligodendrocyte processes were stained with MS#30 (arrow
heads). Scale bars: 10 μm. Super-resolution structured illumination microscopy image (i) of live slices stained with MS#30 (red), then fixed and stained
for MAG (blue) and NF-H (purple). MS#30 reactivity was on oligodendrocyte processes (arrows), including those contacting adjacent axons (arrow head),
and on myelinated MAG+ axons, outside of MAG layer (insert). Scale bar: 2 μm. Diagram of MS#30 rAb binding pattern (j)
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Demyelination by MS#30 plus HC results in microglia
activation, but not astrocyte or neuronal loss
Treatment of slices with MS#30 + HC for 48 h had no
overt effect on astrocyte morphology or network struc-
ture as visualized with GFAP (glial fibrillary acidic pro-
tein) staining. In contrast, NMO#53, which targets
AQP4 on astrocytes [2, 33], caused massive disruption of
the astrocyte network in the presence of HC (Fig. 4a–f ).
Purkinje neuron death was monitored by co-labeling with
calbindin and propidium iodide (PI). Consistent with pre-
vious reports [14], exposure to HC (Iso +HC) induced a
low level of Purkinje cell death at 48 h post-treatment.
Whereas no notable increase of Purkinje cell death was
detected in MS#30 +HC-treated slices when compared to
Iso +HC, Purkinje cell death in the slices treated with
NMO#53 +HC was significantly elevated as previously
described (Fig. 4g–r) [14]. Furthermore, neuronal death
was not limited to Purkinje cells, as coincident
NeuN and PI staining demonstrated a general loss of
neurons throughout the cerebellum of NMO#53 +
HC-treated slices, including the granule cell layer
[14]. Even with extended treatment (72 h), the morph-
ology and survival of astrocytes and neurons remained
unaffected in MS#30 + HC treated slices (data not
shown). Thus, in the presence of HC, MS#30 caused
significant oligodendrocyte cell loss with no apparent
effect on astrocyte and neuronal survival, while
NMO#53 treatment killed astrocytes resulting in
significant downstream loss of both oligodendrocytes
and neurons.
Fig. 2 MS#30 plus human complement (HC) causes robust loss of mature oligodendrocytes but not progenitors. Confocal images of PLP-eGFP in slices
treated with 20 μg/ml MS#30 plus 10% (vol/vol) HC for 8 (a), 12 (b), 24 (c) and 48 h (d) and isotype control rAb (Iso) + HC for 48 h (e). Quantification of
eGFP+ oligodendrocyte cell bodies in slices (f). Cell body count was normalized to control (Iso + HC treated) slice at 8 h. 25X (g, i) and 40X (h, j) objective
confocal images of PLP-eGFP in slices treated with MS#30 alone for 24 and 48 h. 25X (k, m, o, q) and 40X (l, n, p, r) objective confocal images of PLP-eGFP
slices treated with MS#30 alone or MS#30 + HC at indicated time and co-stained with Olig2 (red) and NG2 (blue). Oligodendrocyte progenitors were
identified as Olig2+ NG2+ cells (arrows). Olig2+ NG2- cells were mature oligodendrocytes (arrow heads) and overlapped with PLP-eGFP (25X objective
panels). Quantification of NG2+ Olig2+ oligodendrocyte progenitor cell number in slices (s). Cell count was normalized to control (Iso treated) slice at
24 h. Statistical analyses were performed by multiple unpaired Student’s t test for single comparison (f) or by two-way ANOVA for grouped comparisons
(s). ***: p< 0.001, ****: p< 0.0001, ns: not significant, n= 4. Scale bars: 50 μm
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Microglia activation was assayed by Iba1 (ionized cal-
cium binding adaptor molecule 1) staining (Fig. 5a–r).
Increased numbers of Iba1+ microglia were observed
around oligodendrocytes in MS#30 + HC-treated slices
beginning at 8 h (Fig. 5c, d). Numbers continued to in-
crease with time in focal areas of damage adjacent degen-
erating oligodendrocytes (Fig. 5i, j, s). In NMO#53 +HC
treated slices, microglia activation began later, becoming
clearly prominent at the 48 h time point. Increased num-
bers of robust Iba1+ microglia were dispersed evenly
throughout the folia mirroring the broader area of damage
occurring within NMO#53 +HC slices (Fig. 5k, l, s). Pro-
longed treatment with Iso +HC (48 h) also resulted in in-
creased microglia activation with time of exposure, but at
levels significantly lower than with MS#30 +HC and
NMO#53 +HC (Fig. 5g, h, s). Although treatment with
rAbs alone revealed differences in microglia cell numbers
between Iso and pathogenic MS and NMO rAbs, the
values were far below those observed in the presence of
HC (Fig. 5m–r, s).
Complement activation drives MS#30-mediated
oligodendrocyte cytotoxicity
Based on the requirement for exogenous HC (Figs. 2
and 3), we next examined whether the localization of
activated complement components correlated with the
distinct patterns of tissue injury initiated by myelin- and
AQP4-specific rAbs. To document the presence of
terminal complement activation, slices were immune-
stained for membrane attack complex (MAC). Deposits
of MAC were remarkably enhanced in both MS#30 +HC-
and NMO#53 +HC-treated slices, and co-localized with
the unique patterns of MS#30 and NMO#53 binding. Fol-
lowing 8 h treatment, MAC staining was detected along
oligodendrocyte processes in MS#30 +HC treated slices
(Fig. 6a–d; arrows); whereas in NMO#53 +HC-treated
Fig. 3 MS#30 and NMO rAb #53 (NMO#53) induce demyelination at different rates. Cerebellar slices were treated with MS#30 + HC (a–d, m), or
NMO#53 + HC (e–h, n), or Iso + HC (i–l, o). At the indicated time points, slices were fixed and stained with MBP (red) and NF-H (blue) antibodies.
Confocal images were taken with 25X (a–l) or 63X (m–o) objectives. The coverage of MBP on NF-H+ axons was quantified using a Matlab
algorithm and normalized by control (Iso + HC treated slices) at 8 h (p). Statistical analyses were performed by multiple unpaired Student’s t test.
*: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001, ns: not significant, n = 3-4. Confocal images of MBP and NF-H stained slices treated with rAbs
alone at 48 h (q–s). Scale bars: 100 μm
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slices, MAC was absent from oligodendrocyte processes
(Fig. 6e–h; arrow heads), but co-localized instead with
NMO#53 rAb on astrocytes (Fig. 6e–h; arrows). Using
complement C5-depleted serum, we arrested complement
activation following C3 proteolytic cleavage, preventing
MAC deposition and complement-mediated lysis, but
allowing C3d deposition on complement-targeted cells.
C3d deposition was detected on oligodendrocyte processes
in MS#30 +C5-depleted HC- treated slices (Fig. 6m–p;
arrows), but not in NMO#53 +C5-depleted HC slices
(Fig. 6q–t; arrow heads). Instead, C3d was on cells
presumed to be astrocytes (Fig. 6q–t; arrows) as previously
demonstrated for NMO#53-mediated astrocyte cytotox-
icity [14]. These results demonstrate that complement acti-
vated by MS#30 or NMO#53 is specifically targeted to
oligodendrocytes or astrocytes based on their respective
antigenic specificities. Despite a common effector pathway
of complement activation, MS#30 and NMO#53 displayed
differences in the patterns and kinetics of myelin injury
(Fig. 3) and in downstream pathology, indicating that tar-
geting of different neural cell types and not complement
activation per se, is the likely key to driving pathologic
Fig. 4 MS#30 and NMO#53 have distinct effects on astrocytes and neurons. Immunostaining of astrocytes (a–f) and neurons (g–r) in the slices
treated with rAbs with or without HC for 48 h. GFAP staining to visualize astrocyte morphology and network. Neuronal cell death was monitored
by co-labeling with the dye propidium iodide (PI, red) and Purkinje neuron marker Calbindin (blue). Scale bars: 20 μm
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changes that distinguish NMO and MS demyelination in
cerebellar tissue.
Myelin-binding MS rAbs are less frequent, but present in
multiple MS patient CSF
Since our initial description of MS#30 binding to myelin
[3], we identified additional myelin reactive rAbs from a
CIS patient following their first clinical event, who sub-
sequently developed clinically definite MS. The CSF
plasmablast clone used to generate the myelin-specific
rAb MS#49 represented the largest clone within this pa-
tient’s plasmablast repertoire. MS#49 displayed the same
binding pattern to white matter tracts in mouse cerebel-
lum as previously described in detail for myelin-binding
MS#30 [3]. Staining patterns of both rAbs localized to
cerebellar deep white matter and myelinated axons tra-
versing the granule cell layer, but was abruptly absent at
the molecular layer (Fig. 7b, c). In live staining of cere-
bellar slice cultures, MS#49 also bound the surface of
eGFP+ oligodendrocyte processes and MAG+ myelin-
ated axons (Fig. 7d–g; arrows). MS#49 demonstrated
identical pathology to that observed with MS#30 + HC.
In the presence of HC, MS#49 caused oligodendrocyte
loss and demyelination, while MS#49 alone had no such
effects (Fig. 7h–k). MS#49 plus complement also caused
microglia activation (Fig. 7l) with no damage to astro-
cytes (Fig. 7m). Identical to tissue changes observed after
exposure to MS#30 + HC, MAC staining co-localized
with MS#49 rAb staining along oligodendrocyte pro-
cesses in MS#49 + HC treated slices (Fig. 7n–q; arrows),
demonstrating targeted oligodendrocyte complement
activation.
Discussion
Our studies demonstrate the presence of myelin-specific
plasma blast clones in the CSF of some MS patients.
Using structured illumination microscopy and confocal
microscopy to assess live cell binding, rAb MS#30 and
MS#49 label the surface of oligodendrocyte processes
and myelinated axons adjacent to MOG and exterior to
MAG. More importantly, these myelin-binding MS rAbs
activate the complement pathway and induce robust
oligodendrocyte loss and microglial activation, demon-
strating their potential to contribute to demyelination in
MS patients.
In organotypic cerebellar cultures, exposure to myelin-
specific rAbs +HC resulted in rapid morphologic changes
to oligodendrocytes and their processes accompanied by
terminal complement deposition, microglial activation
and mature oligodendrocyte cell loss, but with preserva-
tion of oligodendrocyte precursors (Figs. 3, 4 and 5). De-
myelination induced by myelin-specific MS rAbs was
distinct from AQP4 autoantibody-mediated demyelin-
ation. Whereas both cerebellar astrocytes and neurons
Fig. 5 Activation of microglia in MS#30 and NMO#53 treated slices. Cerebellar slices treated with rAbs with (a–l) or without (m–r) HC were fixed
at indicated time points and then stained with microglia marker Iba1 (red). Quantification of Iba1+ cell numbers in slices (s). Cell count was
normalized to control (Iso + HC treated slices at 8 h in rAb + HC panel and Iso treated slices at 48 h in rAb only). Statistical analyses were performed
using multiple unpaired Student’s t test. *: p < 0.05, **: p < 0.01, ns: not significant, n = 4. Scale bars: 50 μm
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Fig. 6 (See legend on next page.)
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remain intact at 48 h in slices when exposed to
myelin-specific MS rAbs, AQP4 autoantibody initiated
complement-dependent astrocyte damage, followed by
oligodendrocyte cell death, loss of oligodendrocyte precur-
sors [14] and extensive neuronal cell death (Fig. 4). We
have previously reported that with ongoing astrocyte de-
struction induced by AQP4 autoantibody NMO#53 +HC,
loss of oligodendrocytes increased from 30% at 12 h to
50% by 48 h. Also, approximately 50% of NG2+ Olig2+
oligodendrocyte precursors were lost in slices by 24 h after
treatment with NMO #53 +HC [14]. The damage pattern
in this model was thus consistent with in vivo murine
models of NMO lesion formation that demonstrate initial
astrocyte depletion followed by loss of oligodendrocytes
and progenitors [32]. Rapid Iba1 upregulation in the pres-
ence of myelin-specific rAb plus HC is consistent with the
role of microglia as early tissue-resident sensors of CNS
injury [20]. Activated microglia were observed in focal
areas around degenerating oligodendrocytes in MS#30 +
HC-treated slices beginning at 8 h (Fig. 5), whereas in
NMO#53 +HC treated slices, microglia activation began
later becoming clearly prominent at the 48 h time point
and dispersed evenly throughout the folia. Despite early
complement-mediated killing of astrocytes by NMO#53,
the differences in kinetics of microglia activation in the
cerebellar slice cultures between MS#30 and NMO#53 in-
dicates that microglia activation might be independent of
complement activation. Instead, microglia may be acti-
vated by sensing debris of dead oligodendrocytes and/or
damaged myelin, which leads to clearance of debris. Even
with extended treatment, the morphology and survival of
astrocytes and neurons remained unaffected in slices
treated with MS#30 +HC, suggesting that early microglial
activation may offer a protective or beneficial effect [27].
The distinct patterns of injury induced by the MS and
NMO antibodies in the presence of complement indicate
that the target of complement-dependent cytotoxicity, and
not activation of the complement cascade itself, is import-
ant for delineating the spectrum of glial and neuronal in-
jury (Fig. 8). The important supporting role of astrocytes
to both oligodendrocytes and neurons [11] distinguishes
damage by NMO antibody from that occurring by direct
targeting of oligodendrocyte processes. Our results further
distinguish these demyelinating disorders and their mech-
anisms of oligodendrocyte loss [1, 16, 23, 32, 33].
Extensive investigation has been performed to patho-
logically characterize and classify MS lesions. The sta-
ging system distinguishes active, chronic active, inactive
and pre-active lesions [30]. In relapsing-remitting MS,
the lesions are often active or chronic active, with axonal
transections and massive infiltration and accumulation of
inflammatory cells. In the progressive stage of disease, in-
active lesions are more typically characterized by axonal
loss, astrogliosis and minor infiltration of immune cells
[26]. In the majority of active MS lesions, tissue histopath-
ology demonstrates oligodendrocyte apoptosis, deposition
of immunoglobulin and terminally activated complement
[15] or T cell-mediated as separate and distinct cause of
CNS demyelination, whereas others have reported oligo-
dendrocyte apoptosis in the absence of inflammation as
the earliest event in lesion development damage [25]. Im-
portantly, our cerebellar slice model recapitulates some of
the reported pathologic features of active MS lesions and
provides strong evidence that antibodies produced by B
cell populations expanded within the CNS compartment
have the potential to drive complement-dependent oligo-
dendrocyte cytotoxicity and contribute to lesion formation.
Given the absence of a peripheral immune compartment in
the cerebellar slice culture model, methodologic restrictions
prevent the replication of some seminal features of inflam-
matory MS lesions, such as myelin phagocytosis, axonal
loss and astrogliosis in this slice system. The development
of an in vivo model of MS rAb antibody injury should allow
investigators to further distinguish attributes of antibody-
mediated from cell-mediated pathologies.
We have currently cloned myein-specific rAbs from 2
of 4 MS patients analyzed, but their antigenic target re-
mains unknown. Localization of Ab binding to the outer
surface of oligodendrocyte processes and myelin sug-
gests a limited possibility of candidate antigens. MS#30
failed to bind to HEK cells expressing the myelin surface
protein MOG [22], nor did it bind to the myelin glyco-
lipids sulfatide and galC on lipid arrays [5]. We postulate
that higher order multimolecular complexes may be driv-
ing antigen specificity. In addition to recognizing myelin-
enriched antigens, antibodies cloned from other MS CSF
plasmablasts bind to antigens expressed on astrocytes and
neurons [3, 13]. It is possible that these antibodies may in-
duce secondary demyelination as observed with AQP4-
targeted rAbs [32, 33]. The impact of injured astrocytes
(See figure on previous page.)
Fig. 6 MS#30 and NMO#53 cause cytotoxicity to targeted cells via complement activation. PLP-eGFP slices were treated with rAb + HC (a–l) or
rAb + C5-depleted HC (m–x) for 8 h and then stained for MAC and C3d deposition, respectively. Deposits of MAC (red) or C3d (red) were detected
along PLP-eGFP+ oligodendrocyte processes and co-localized with MS#30 rAb (blue) in MS#30 + HC treated slices (a–d, m–p; arrows); whereas in
NMO#53 + HC treated slices (e–h, q–t), MAC was co-localized with NMO#53 rAb (blue), which specifically labels astrocytes and end-foot processes
(arrows), but was absent from oligodendrocyte processes (arrow heads). MAC and C3d staining were notably increased in MS#30 + HC or NMO#53 + HC
treated slices when compared to Iso + HC treated ones (i–l, u–x). Scale bar: 25 μm
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and neurons on oligodendrocytes through glia-glia
[12, 17] and axon-glia interactions [6, 7, 31] has been well
documented. These antibodies may also cause primary de-
generation or facilitate the removal of cellular debris.
The results of autologous hematopoietic stem cell
transplantation (AHSCT) [19] and therapeutic B cell de-
pletion [8] have called into question the role of antibody
in MS lesion formation, despite numerous examples of
Fig. 7 MS rAb#49 (MS#49) binds to myelin and causes demyelination in presence of HC. Staining of mouse cerebellum with isotype control rAb (Iso)
is negative (a) whereas MS #30 rAb staining (b) showed localization in cerebellar deep white matter (DWM) and myelinated tracks within the granule
cell layer (GCL). Note the abrupt absence of staining at the molecular layer (ML). A similar staining pattern was observed with MS#49 rAb (c). All rAbs
(green) were used at 20 μg/ml. Scale bar: 50 μm. MS#49 bound to oligodendrocyte processes and myelinated MAG+ axons in cultured mouse
cerebellar slices (d–g). Live slices prepared from PLP-eGFP mouse pups were incubated with 20 μg/ml MS#49 rAb (red) then fixed and immunostained
with anti-human secondary and MAG (blue). MS#49 live binding signals were co-localized with PLP-eGFP+ oligodendrocyte processes and MAG+
myelinated axons (stained with NF-H, arrows). Scale bar: 10 μm. MS#49 induced complement-dependent cytotoxicity to mature oligodendrocytes and
demyelination. Confocal images of PLP-eGFP in slices treated with MS#49 −/+ HC for 48 h (h, i) and then fixed and stained with MBP (red) and NF-H
(blue) antibodies (j, k). Scale bar: 100 μm. MS#49 + HC induced microglia activation with no effect on astrocytes. PLP-eGFP slices treated with MS#49 +
HC for 48 h were fixed and stained with Iba1 (l) and GFAP (m). Scale bar: 50 μm. MS#49 treatment activates the complement pathway on oligodendrocyte
processes (n–q). PLP-eGFP slices were treated with MS#49 +HC for 48 h and stained with MAC (red). Deposits of MAC were detected along PLP-eGFP+
oligodendrocyte processes and co-localized with MS#49 rAb (blue, arrows). Scale bar: 25 μm
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antibody and complement-mediated demyelination in
post-mortem MS autopsy specimens. In autopsy speci-
mens from AHSCT-treated MS patients, extensive de-
myelination and axonal degeneration are observed in the
presence of innate immune activation, but without not-
able B cell infiltration [19]. Following peripheral B cell
depletion, significant reduction in inflammatory lesion
formation is observed in the absence of changes in intra-
thecal IgG synthesis or oligoclonal bands [9, 10]. How-
ever, it must be noted that antibody deposition and
complement activation were not directly evaluated in
post-AHSCT lesions; and antibody-mediated comple-
ment cytotoxicity in MS patients may be suppressed fol-
lowing B cell depletion by limited serum complement
extravasation into the CNS from the rapid and extensive
reduction of blood-brain barrier breakdown.
Conclusions
In conclusion, we have identified a subset of early MS
patients with expanded CSF plasma blast clones specific
for antigenic epitopes present on the surface of oligo-
dendrocyte processes and myelin. Our studies using an
ex vivo slice model reveal that these myelin-specific anti-
bodies drive complement-dependent oligodendrocyte loss
and demyelination and could be contributors to type II
MS lesions. Whether pathogenic myelin-specific Abs are
rare or more common, both within MS CSF plasmablast
repertoires and amongst a wider spectrum of MS patients
are crucial questions that will require identification of the
relevant myelin antigens and the development of assays to
screen a large sampling of MS CSF and serum.
Additional file
Additional file 1: Video S1. 3D movie reconstructed by super-resolution
structured illumination microscopy (SIM) imaging of live organotypic mouse
cerebellar slices stained with MS#30 (red), then fixed and stained for MAG
(blue) and NF-H (purple). MS#30 reactivity was on oligodendrocyte processes,
including those contacting adjacent axons, and on myelinated MAG+ axons,
outside of MAG layer. Scale bar: 2 μm. (MPG 90340 kb)
Fig. 8 Schematic of distinct effects on glial and neuronal cells induced by MS and NMO antibodies in cerebellar slices. MS myelin-specific (myelin + Ab,
such as MS#30 and MS#49) and NMO AQP4-specific (AQP4+ Ab, such as NMO#53) antibodies cause distinct patterns of complement-dependent
tissue injury. Beginning at 8 h post-treatment, myelin-specific MS rAb MS#30 targets oligodendrocyte processes and induce rapid and increasing loss
of oligodendrocytes, demyelination and microglia activation in the presence of complement (+HC). No significant effects on oligodendrocyte
progenitors, neurons or astrocytes are observed. In contrast, NMO AQP4+ rAb targets astrocytes and induces robust complement-dependent astrocyte
destruction. At 8 h post-treatment, astrocytes are swollen and the network of astrocytic processes is disrupted. At 48 h, massive destruction of the
astrocyte network is apparent. Following astrocyte damage, there is a sequential loss of mature oligodendrocytes, demyelination, oligodendrocyte
progenitor reduction, microglia activation and neuronal death [14]. AST: astrocyte, OL: oligodendrocyte, OPC: oligodendrocyte progenitor cell, N:
neuron, MG: microglia
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